Advertisement

Topics

NICE backs Lilly’s JAK inhibitor Olumiant for RA

02:50 EDT 30 Jun 2017 | PharmaTimes

A novel treatment option for some patients with rheumatoid arthritis (RA) could soon be routinely available on the NHS, after cost regulators ruled Eli Lilly’s Olumiant to be cost-effective with the inclusion of a confidential patient access scheme.

Original Article: NICE backs Lilly’s JAK inhibitor Olumiant for RA

NEXT ARTICLE

More From BioPortfolio on "NICE backs Lilly’s JAK inhibitor Olumiant for RA"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Orthopedics
Arthroplasty Joint Disorders Orthopedics Spinal Cord Disorders Orthopedics is the science or practice of correcting deformities caused by disease or damage to the bones and joints of the skeleton. This specialized branch of surgery may ...